Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
Want to see OLMA full AI Analyst Report?
OLMA Stock Chart & Stats
$16.49
$0.55(10.50%)
At close: 4:00 PM EST
$16.49
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$3.89 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.94M
Market Cap
$1.44B
Enterprise Value$1.39B
Total Cash (Recent Filing)$505.44M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 12, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding87,156,960
10 Day Avg. Volume824,259
30 Day Avg. Volume1,944,621
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.41K
Enterprise Value/Ebitda-7.96
Forecast
1Y Price Target
$42.50Price Target Upside157.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$2.05M
Bulls Say, Bears Say
Bulls Say
Financial Strength And CollaborationA robust cash position combined with a collaboration to evaluate combination regimens with a large pharmaceutical partner reduces development risk and supports continued execution across key programs.
KAT6 Inhibitor Franchise ExpansionEarly clinical signals from the KAT six inhibitor program could broaden the company's oncology franchise beyond breast cancer if the candidate matches competitor efficacy while demonstrating improved tolerability.
Mutation-specific EfficacyStrong single-agent activity of palazestrant in patients with a specific estrogen receptor mutation supports a meaningful progression-free survival advantage in that subgroup, a distinction that could set the drug apart from competitors.
Bears Say
Adjuvant Competitive LeadA major competitor's advance in adjuvant development raises the bar for long, duplicative studies and could constrain commercial prospects for first-line indications.
Competitor Trial Failure ReadthroughFailure of a related late-stage oral selective estrogen receptor degrader trial creates uncertainty about class performance and could lower expectations for comparable first-line programs.
Control Arm Strength And Combination RiskStronger than expected performance of control treatments and mixed data on adding a cell-cycle inhibitor may reduce the observable advantage of an oral selective estrogen receptor degrader when tested in first-line combinations.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $3.89 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $1.44B.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 25 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Mar 16, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.514 by $0.014.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.53.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 87,156,960 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.514. Following the earnings report the stock price went up 12.848%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.50 (157.73% Upside)
$42.50 (157.73% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
291.68%
12-Months-Change
Fundamentals
Return on Equity
-42.90%
Trailing 12-Months
Asset Growth
21.80%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Stock 12 Month Forecast
Average Price Target
$42.50
▲(157.73% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
Currently, No data available
---